Palma Fedele

968 total citations
56 papers, 591 citations indexed

About

Palma Fedele is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Palma Fedele has authored 56 papers receiving a total of 591 indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Oncology, 30 papers in Pulmonary and Respiratory Medicine and 20 papers in Cancer Research. Recurrent topics in Palma Fedele's work include HER2/EGFR in Cancer Research (24 papers), Cancer Treatment and Pharmacology (21 papers) and Advanced Breast Cancer Therapies (20 papers). Palma Fedele is often cited by papers focused on HER2/EGFR in Cancer Research (24 papers), Cancer Treatment and Pharmacology (21 papers) and Advanced Breast Cancer Therapies (20 papers). Palma Fedele collaborates with scholars based in Italy, United States and Norway. Palma Fedele's co-authors include Saverio Cinieri, Laura Orlando, Nicola Calvani, Antonella Marino, P. Rizzo, Anna Santoro, Valeria Sanna, Maria Cinefra, Antonio Cusmai and P. De Santis and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Annals of Oncology.

In The Last Decade

Palma Fedele

49 papers receiving 580 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Palma Fedele Italy 14 327 217 175 154 75 56 591
Sibylle Loibl Germany 11 304 0.9× 156 0.7× 214 1.2× 144 0.9× 55 0.7× 45 500
Derek Dustin United States 8 192 0.6× 228 1.1× 169 1.0× 125 0.8× 80 1.1× 14 464
Nicola Cresti United Kingdom 13 331 1.0× 216 1.0× 83 0.5× 80 0.5× 80 1.1× 34 639
Patrick Cohen France 12 209 0.6× 135 0.6× 96 0.5× 141 0.9× 69 0.9× 26 556
Tsion Z. Minas United States 16 200 0.6× 310 1.4× 125 0.7× 128 0.8× 35 0.5× 27 645
Caterina Aversa Italy 12 285 0.9× 210 1.0× 108 0.6× 222 1.4× 30 0.4× 32 553
Syed A. Ahmed United States 10 304 0.9× 224 1.0× 149 0.9× 107 0.7× 58 0.8× 16 644
Maria Rosa Cappelletti Italy 13 312 1.0× 213 1.0× 239 1.4× 251 1.6× 46 0.6× 32 635
Rossella Martinello Italy 13 431 1.3× 134 0.6× 229 1.3× 210 1.4× 27 0.4× 26 626
Hanan Ahmed Wahba Egypt 8 238 0.7× 226 1.0× 140 0.8× 94 0.6× 31 0.4× 24 529

Countries citing papers authored by Palma Fedele

Since Specialization
Citations

This map shows the geographic impact of Palma Fedele's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Palma Fedele with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Palma Fedele more than expected).

Fields of papers citing papers by Palma Fedele

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Palma Fedele. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Palma Fedele. The network helps show where Palma Fedele may publish in the future.

Co-authorship network of co-authors of Palma Fedele

This figure shows the co-authorship network connecting the top 25 collaborators of Palma Fedele. A scholar is included among the top collaborators of Palma Fedele based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Palma Fedele. Palma Fedele is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Fedele, Palma, Matteo Landriscina, Antonio Cusmai, et al.. (2024). Evaluating CDK4/6 Inhibitor Therapy in Elderly Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer: A Retrospective Real-World Multicenter Study. Cancers. 16(20). 3442–3442. 2 indexed citations
3.
Pinto, Antonio, Valeria Sanna, Assunta Melaccio, et al.. (2024). Synergizing Immunotherapy and Antibody–Drug Conjugates: New Horizons in Breast Cancer Therapy. Pharmaceutics. 16(9). 1146–1146. 9 indexed citations
4.
Botticelli, Andrea, Alessandra Fabi, Alessandro Rossi, et al.. (2024). Trastuzumab deruxtecan in patients with breast cancer with brain metastases: The DE-REAL study.. Journal of Clinical Oncology. 42(16_suppl). 1032–1032. 1 indexed citations
5.
Fedele, Palma, Matteo Landriscina, Antonio Cusmai, et al.. (2024). Standard Versus Reduced CDK4/6 Inhibitor Therapy in Elderly Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer: An Observational Multicenter Study. Journal of Clinical Medicine. 13(23). 7441–7441. 1 indexed citations
6.
7.
8.
Laface, Carmelo, Riccardo Memeo, Anna Santoro, et al.. (2023). Immunotherapy and Pancreatic Cancer: A Lost Challenge?. Life. 13(7). 1482–1482. 11 indexed citations
9.
Laface, Carmelo, Francesco Giuliani, Assunta Melaccio, et al.. (2023). The Treatment Landscape of Elderly Patients with Hormone Receptor-Positive Her2 Negative Advanced Breast Cancer: Current Perspectives and Future Directions. Journal of Clinical Medicine. 12(18). 6012–6012. 1 indexed citations
10.
Sanna, Valeria, Palma Fedele, Giulia Deiana, et al.. (2022). Edmonton Symptom Assessment Scale may reduce medical visits in patients undergoing chemotherapy for breast cancer. World Journal of Clinical Oncology. 13(7). 577–586. 4 indexed citations
11.
Fedele, Palma, Valeria Sanna, Alessandro Fancellu, et al.. (2020). De-escalating cancer treatments during COVID 19 pandemic: Is metronomic chemotherapy a reasonable option?. Critical Reviews in Oncology/Hematology. 157. 103148–103148. 7 indexed citations
12.
Orlando, Laura, Antonio Febbraro, Claudio Zamagni, et al.. (2019). Eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer patients: safety and efficacy. An Italian experience. Tumori Journal. 106(4). 301–305. 2 indexed citations
13.
Orlando, Laura, et al.. (2016). Response of Extensive Breast Cancer Skin Metastases to Rechallenge with Trastuzumab Together with Low-Dose Chemotherapy and Insulin. Tumori Journal. 102(2_suppl). S26–S28. 2 indexed citations
14.
Orlando, Laura, Giovanna Giordano, Claudio Zamagni, et al.. (2016). Safety and efficacy of eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer (ABC) patients. An Italian multicenter experience. Annals of Oncology. 27. vi76–vi76.
15.
Orlando, Laura, Palma Fedele, Caterina Fontanella, et al.. (2015). Lapatinib and continuous metronomic capecitabine in HER2 positive advanced breast cancer (ABC): a single center experience. Annals of Oncology. 26. vi17–vi17.
16.
Fedele, Palma, et al.. (2015). Recent advances in the treatment of hormone receptor positive HER2 negative metastatic breast cancer. Critical Reviews in Oncology/Hematology. 94(3). 291–301. 21 indexed citations
17.
Calvani, Nicola, Franco Morelli, Vincenzo Emanuele Chiurì, et al.. (2013). Prolonged exposure to tyrosine kinase inhibitors or early use of everolimus in metastatic renal cell carcinoma: are the two options alike?. Medical Oncology. 30(2). 578–578. 8 indexed citations
18.
Fedele, Palma, Antonella Marino, Laura Orlando, et al.. (2011). Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer. European Journal of Cancer. 48(1). 24–29. 76 indexed citations
19.
Orlando, Laura, Palma Fedele, Nicola Calvani, et al.. (2010). Molecularly targeted endocrine therapies for breast cancer. Cancer Treatment Reviews. 36. S67–S71. 58 indexed citations
20.
Orlando, Laura, Marco Colleoni, Palma Fedele, et al.. (2007). Management of advanced breast cancer. Annals of Oncology. 18. vi74–vi76. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sibylle Loibl Breakdown of academic impact, for papers by Derek Dustin Breakdown of academic impact, for papers by Nicola Cresti Breakdown of academic impact, for papers by Patrick Cohen Breakdown of academic impact, for papers by Tsion Z. Minas Breakdown of academic impact, for papers by Caterina Aversa Breakdown of academic impact, for papers by Syed A. Ahmed Breakdown of academic impact, for papers by Maria Rosa Cappelletti Breakdown of academic impact, for papers by Rossella Martinello Breakdown of academic impact, for papers by Hanan Ahmed Wahba
Rankless by CCL
2026